Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (ACB) is a globally recognized leader in medical and recreational cannabis production, operating advanced facilities that meet stringent international standards. This page serves as the definitive source for verified news and official announcements impacting ACB's market position and strategic initiatives.
Access real-time updates including quarterly earnings, regulatory compliance milestones, product launches, and partnership agreements. Investors will find essential details on operational expansions, while analysts gain insights into ACB's research-driven approach to cannabis cultivation and global distribution strategies.
Key coverage areas span clinical trial developments, international market entries, sustainability initiatives, and innovations in cannabis-derived health products. All content is curated to meet investor-grade reliability standards, sourced directly from company filings and accredited industry publications.
Bookmark this page for streamlined access to ACB's evolving narrative in the global cannabis sector. Combine our updates with Stock Titan's financial tools to monitor market reactions and long-term trends.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), Canada's largest medical cannabis company, has announced its participation in TD Cowen's 9th Annual Future of the Consumer Conference in New York City. CFO Simona King will engage in a fireside chat and investor meetings on June 3, 2025, at 2:45pm EST.
The discussion, hosted by TD Cowen's VP of Equity Research Derek Lessard, will focus on Aurora's international market expansion, medical cannabis landscape developments, Canadian manufacturing progress, and market dynamics. A live audio webcast will be available, with replay access for approximately 90 days through Aurora's investor relations website.
Aurora Cannabis has completed a $3 million investment in its Pemberton, British Columbia manufacturing facility, now renamed to Aurora Alpine. The multi-year upgrades have significantly improved the facility's performance, combining proprietary genetics with advanced engineering to optimize cultivation conditions.
Key achievements include:
- Doubled yield and potency, reaching 33.7% record levels
- GACP certification enabling international exports
- Enhanced operational efficiency and cultivation precision
The facility, formerly known as Whistler Medical Marijuana Company, was licensed in 2019. Located overlooking Mount Currie in the Pemberton Valley, the renamed Aurora Alpine reflects the company's commitment to excellence in cannabis production. The improvements strengthen Aurora's position as a global leader in medical cannabis, particularly in international markets through its premium product exports.
Aurora Cannabis (NASDAQ: ACB) has launched its first medical cannabis concentrates for patients in the United Kingdom, expanding its global medical cannabis portfolio. The company introduced two proprietary cultivar-specific 1.2g resin cartridges: Sourdough (indica) and Electric Honeydew (sativa).
The inhalable cartridges offer key benefits including exceptional flavor profiles, high potency for consistent dosing, and a user-friendly design for convenient and discreet consumption. The products are manufactured in TGA-GMP certified facilities without additives, ensuring premium quality and safety standards.
This launch follows successful implementations in Canada and Australia, demonstrating Aurora's commitment to expanding patient access to high-quality medical cannabis globally. The products are available nationwide through cannabis retailers, with patients advised to consult their doctors or clinics for more information.
Aurora Cannabis (NASDAQ: ACB) has been recognized on The Globe & Mail's 2025 Report on Business Women Lead Here list for its outstanding executive gender diversity. The company, Canada's largest medical cannabis provider, boasts 43% female representation in its executive leadership team.
The recognition highlights Aurora's commitment to diversity and inclusion, as emphasized by CFO Simona King. In 2022, the company established the Women Empowerment Network (WEN), an employee resource group focused on advancing women's professional development through learning and community engagement opportunities.
This achievement will be featured in the April 2025 issue of Report on Business magazine, distributed with The Globe and Mail on March 29, 2025.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), Canada's largest medical cannabis company, will participate in the inaugural 2025 Global Cannabis Regulatory Summit (GCRS) in Washington, D.C. on March 26-27, 2025. The event, hosted by Artemis Growth Partners within the U.S. Capitol Complex, brings together regulators, Congress members, international policy experts, and cannabis industry executives.
Rick Savone, Senior Vice President of Global Government Relations at Aurora, emphasizes the company's role in advocating for policy reform globally. Aurora will participate in panel discussions focusing on:
- Differences between medical and adult-use cannabis based on international political and regulatory consensus
- How mature medical cannabis markets can guide regulations in emerging markets
FAQ
What is the current stock price of Aurora Cannabis (ACB)?
What is the market cap of Aurora Cannabis (ACB)?
